Analysis of the ten-eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms

Annals of Clinical and Laboratory Science

Volumn 44, Issue 2, 2014, Pages 173-179

  Ha, Jung Sook ^a   Jeon, Dong Seok ^a   Kim, Jae Ryong ^a   Ryoo, Nam Hee ^a   Suh, Jang Soo ^b  

^a Keimyung University School of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

JAK2 V617F; Myeloproliferative neoplasm; TET2

Indexed keywords

HEMOGLOBIN; DNA BINDING PROTEIN; ONCOPROTEIN; STOP CODON; TET2 PROTEIN, HUMAN;

ADULT; AGE; ALLELE; ARTICLE; BLEEDING; EXON; GENE; GENOME; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; JAK2 GENE; KARYOTYPING; LEUKOCYTE COUNT; LOSS OF FUNCTION MUTATION; LYMPHOCYTE COUNT; MONOCYTE; MUTATION RATE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEUTROPHIL COUNT; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; TET2 GENE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; AGED; BONE MARROW; BONE MARROW CANCER; FEMALE; FRAMESHIFT MUTATION; GENETICS; MALE; MIDDLE AGED; MISSENSE MUTATION; MUTATION; PATHOLOGY; STOP CODON;

ADULT; AGED; BONE MARROW; BONE MARROW NEOPLASMS; CODON, NONSENSE; DNA-BINDING PROTEINS; FEMALE; FRAMESHIFT MUTATION; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTO-ONCOGENE PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84899736426     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
4. Plo I, Vainchenker W. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma 2009;9 Suppl 3:S329-339.
5. Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. The Journal of biological chemistry J Biol Chem 2008;283:5258-5266.
6. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer Cancer 2009;115:3842-3847.
7. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
8. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723-1735.
9. Globisch D, Munzel M, Muller M, Michalakis S, Wagner M Koch S, Bruckl T, Biel M, Carell T. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One 2010;5:e15367.
10. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002;62:4075-4080.
11. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
12. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M Vainchenker W, Bernard OA. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-2301.
13. Couronne L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D, Dastugue N, Mugneret F, Lafage M Gachard N, Nadal N, Bernard OA, Nguyen-Khac F. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010;24:201-203.
14. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-842.
15. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900-904.
16. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-1345.
17. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843.
18. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC Xu M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118:4509-4518.
19. Martinez-Aviles L, Besses C, Alvarez-Larran A, Torres E Serrano S, Bellosillo B. TET2, ASXL1, IDH1, IDH2, and c- CBL genes in JAK2-and MPL-negative myeloproliferative neoplasms. Hematol 2012;91:533-541.
20. Nguyen-Khac F, Lesty C, Eclache V, Couronne L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F Gachard N, Nadal N, Lippert E, Struski S, Dastugue N Cabrol C, Bernard OA, Groupe Francophone de Cytogenetique H. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer 2010;49:919-927.
21. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL Verstovsek S. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-452.
22. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-6410.
23. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C Lazzarino M, Cazzola M. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-1579.